Therapeutic Oligonucleotides for Cystic Fibrosis Mutations
Summary
USPTO published patent application US20260109986A1 on April 23, 2026, filed by applicants on October 13, 2023 (application no. 19117758). The application discloses therapeutic splice-switching oligonucleotides designed to correct specific CFTR gene mutations including 1811+1.6kb G>T, 1811+1.6kb A>G, 1811+1.6kb T>A, and W1282X, for the treatment of cystic fibrosis in a subject. Inventors: Silvia Kreda, Yan Dang, Aiguo Ni. This is a routine patent publication creating no compliance obligations.
About this source
GovPing monitors USPTO Patent Applications - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 258 changes logged to date.
What changed
USPTO published patent application US20260109986A1 disclosing novel splice-switching oligonucleotides designed to correct specific CFTR gene mutations (1811+1.6kb G>T, A>G, T>A, and W1282X) implicated in cystic fibrosis. The application covers methods of treatment using these oligonucleotides for CF in human subjects.
There are no compliance obligations arising from this publication. Patent applicants and competitors in the pharmaceutical/biotechnology sector may use this disclosure to assess the intellectual property landscape around CFTR splice-correction therapies. No regulatory action or response is required from any party.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
THERAPEUTIC OLIGONUCLEOTIDES TO CORRECT CYSTIC FIBROSIS MUTATIONS
Application US20260109986A1 Kind: A1 Apr 23, 2026
Inventors
Silvia Kreda, Yan Dang, Aiguo Ni
Abstract
This invention relates to the finding that novel splice switching oligonucleotides can correct splicing mutations. Moreover, the invention relates to using the novel splice switching oligonucleotides to correct a 1811+1.6kb G>T (c. 1679+1643G>T). 1811+1.6kb A>G (c. 1679+1634A>G), 1811+1.6kb T>A (c. 1679+1650T>A), or W1282X (c.3846G>A) mutation in a pre-mRNA produced from the human CFTR gene and methods of using the same for treatment of cystic fibrosis (CF) in a subject.
CPC Classifications
C12N 15/1138 A61K 31/712 A61K 31/7125 A61K 45/06 A61K 48/005 A61P 11/00 C12N 2310/11 C12N 2310/31 C12N 2310/321 C12N 2310/3233 C12N 2310/3513 C12N 2320/33
Filing Date
2023-10-13
Application No.
19117758
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.